Leadership Advancing Our ALS Mission

Our team brings together scientists, inventors and healthcare executives with expertise in ALS, neurodegenerative diseases, immune biology and biotechnology commercialization.

Published Research and Operating Experience

Combining published research with experience in biomarker development and healthcare innovation, we are committed to advancing a biomarker-guided therapeutic approach for ALS and improving the lives of patients and families.

Kevin Combs

Kevin Combs

Chief Executive Officer and Chairman

Kevin Combs serves as Chief Executive Officer and Chairman of NK Immuno T.

Read Bio →
Tom Calcagnini

Tom Calcagnini

Chief Financial Officer

Tom Calcagnini serves as Chief Financial Officer of NK Immuno T.

Read Bio →
Dr. Tapan K. Khan

Dr. Tapan K. Khan

Chief Operating Officer

A biotechnology entrepreneur with more than 20 years of experience, Dr. Khan leads collaborations, funding initiatives, product development and regulatory affairs.

Read Bio →
Dr. Kawaljit Kaur

Dr. Kawaljit Kaur

Chief Scientific Officer and Director

Dr. Kaur leads ALS research strategy, biomarker development and preclinical planning, drawing on expertise in immune regulation and translational medicine.

Read Bio →
Robert Zell Seach

Robert “Zell” Seach

Founder, Secretary and Director

Zell brings pharmaceutical-industry and executive leadership experience in business development, strategic planning and organizational growth.

Read Bio →
Mark Zilner

Mark Zilner, RPh.

Treasurer and Director

A pharmacist and healthcare entrepreneur with more than 35 years of experience, Mark brings expertise in pharmacy operations, financial oversight and corporate management.

Read Bio →

Board of Directors

Company oversight supporting our scientific and corporate development.

  • Kevin CombsChairman
  • Robert “Zell” SeachDirector
  • Mark Zilner, RPh.Director
  • Dr. Kawaljit KaurDirector